Cancer and Systemic Lupus Erythematosus

Alexandra Ladouceur; Basile Tessier-Cloutier; Ann E. Clarke; Rosalind Ramsey-Goldman; Caroline Gordon; James E. Hansen; Sasha Bernatsky

doi:10.1016/j.rdc.2020.05.005

Cancer and Systemic Lupus Erythematosus

Alexandra Ladouceur, Basile Tessier-Cloutier, Ann E. Clarke, Rosalind Ramsey-Goldman, Caroline Gordon, James E. Hansen, Sasha Bernatsky^*

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. A decreased risk of breast, ovarian, and endometrial cancer might be driven by hormonal factors or lupus-related antibodies, but these links have not been proved.

Original language	English (US)
Pages (from-to)	533-550
Number of pages	18
Journal	Rheumatic Disease Clinics of North America
Volume	46
Issue number	3
DOIs	https://doi.org/10.1016/j.rdc.2020.05.005
State	Published - Aug 2020

Keywords

Cancer
Epidemiology
Malignancy
Systemic lupus erythematosus

ASJC Scopus subject areas

Rheumatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.rdc.2020.05.005

Cite this

@article{20e83c410ba747b0ab5dd9df62d09f72,

title = "Cancer and Systemic Lupus Erythematosus",

abstract = "Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. A decreased risk of breast, ovarian, and endometrial cancer might be driven by hormonal factors or lupus-related antibodies, but these links have not been proved.",

keywords = "Cancer, Epidemiology, Malignancy, Systemic lupus erythematosus",

author = "Alexandra Ladouceur and Basile Tessier-Cloutier and Clarke, {Ann E.} and Rosalind Ramsey-Goldman and Caroline Gordon and Hansen, {James E.} and Sasha Bernatsky",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = aug,

doi = "10.1016/j.rdc.2020.05.005",

language = "English (US)",

volume = "46",

pages = "533--550",

journal = "Rheumatic Disease Clinics of North America",

issn = "0889-857X",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Cancer and Systemic Lupus Erythematosus

AU - Ladouceur, Alexandra

AU - Tessier-Cloutier, Basile

AU - Clarke, Ann E.

AU - Ramsey-Goldman, Rosalind

AU - Gordon, Caroline

AU - Hansen, James E.

AU - Bernatsky, Sasha

PY - 2020/8

Y1 - 2020/8

N2 - Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. A decreased risk of breast, ovarian, and endometrial cancer might be driven by hormonal factors or lupus-related antibodies, but these links have not been proved.

AB - Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. A decreased risk of breast, ovarian, and endometrial cancer might be driven by hormonal factors or lupus-related antibodies, but these links have not been proved.

KW - Cancer

KW - Epidemiology

KW - Malignancy

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85086384388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086384388&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2020.05.005

DO - 10.1016/j.rdc.2020.05.005

M3 - Review article

C2 - 32631602

AN - SCOPUS:85086384388

SN - 0889-857X

VL - 46

SP - 533

EP - 550

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

IS - 3

ER -

Cancer and Systemic Lupus Erythematosus

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this